Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice
-
Iman Fatemi
,
Ali Shamsizadeh
,
Ali Roohbakhsh
,
Fatemeh Ayoobi
,
Mohammad Hossein Sanati
,
Manijeh Motevalian
Abstract
Orexin A and B are hypothalamic peptides with a wide variety of effects such as anti-inflammation and neuroprotection. Impaired function of orexin system has been reported in some neurodegenerative diseases like Parkinson, Huntington and Alzheimer. In this study, the mRNA expression levels of some hypothalamic peptides were investigated in C57BL/6 female mice with experimental autoimmune encephalomyelitis (EAE). Animals were randomly divided into two control and EAE groups. EAE was induced by administration of myelin oligodendrocyte glycoprotein (MOG) with complete Ferund’s adjuvant and pertussis toxin. Twenty-first days following immunization, mice were decapitated to remove the brains. Then, the expression profiles of prepro-orexin, orexin 1 receptors (OX1R) and orexin 2 receptors (OX2R) in hypothalamic region were assessed using real-time PCR method. In this study, we found a considerable increase in the mRNA expression of OX1R and OX2R following EAE induction in C57BL/6 mice. Elevation levels of OX1R and OX2R following EAE induction suggest that alteration in orexinergic system may involve in pathogenesis of multiple sclerosis.
1. Brück W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. Journal of the neurological sciences.2003;206(2):181-5.
2. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease. 2010;1802(1):66-79.
3. Nagaraj K, Taly AB, Gupta A, Prasad C, Christopher R.Depression and sleep disturbances in patients with multiple sclerosis and correlation with associated fatigue. J Neurosci Rural Pract. 2013;4(4):387-91.
4. Benedict RH, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. Journal of the neurological sciences. 2006;245(1):67-72.
5. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain.2006;129(8):1953-71.
6. Pál E, Yamamura T, Tabira T. Autonomic regulation of experimental autoimmune encephalomyelitis in IL-4 knockout mice. Journal of neuroimmunology.1999;100(1):149-55.
7. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein- coupled receptors that regulate feeding behavior. Cell.1998;92(4):573-85. Epub 1998/03/10.
8. Suzuki R, Shimojima H, Funahashi H, Nakajo S, Yamada S, Guan J-L, et al. Orexin-1 receptor immunoreactivity in chemically identified target neurons in the rat hypothalamus. Neuroscience letters. 2002;324(1):5-8.
9. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, et al. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain research. 2010;1314:74-90. Epub 2009/10/10.
10. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proceedings of the National Academy of Sciences. 1999;96(19):10911-6.
11. Schwartz MW. Orexins and appetite: the big picture of energy homeostasis gets a little bigger. Nature medicine.1998;4(4):385-6.
12. Al‐Barazanji K, Wilson S, Baker J, Jessop D, Harbuz M.Central orexin‐A activates hypothalamic‐pituitary‐adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. Journal of neuroendocrinology. 2001;13(5):421-4.
13. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain research. 2000;873(1):181-7.
14. Harada S, Fujita-Hamabe W, Tokuyama S. Effect of orexin-A on post-ischemic glucose intolerance and neuronal damage. Journal of pharmacological sciences.2011;115(2):155-63.
15. Bülbül M, Tan R, Gemici B, Öngüt G, İzgüt-Uysal VN.Effect of orexin-a on ischemia-reperfusion-induced gastric damage in rats. Journal of gastroenterology.2008;43(3):202-7.
16. Yuan L-b, Dong H-l, Zhang H-P, Zhao R-n, Gong G, Chen X-m, et al. Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat. Anesthesiology. 2011;114(2):340-54.
17. Butterick TA, Nixon JP, Billington CJ, Kotz CM. Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model. Neuroscience letters.2012;524(1):30-4.
18. Long-Biao C, Bo-Wei L, Xiao-Hang J, Lin Z, Juan S.Progressive changes of orexin system in a rat model of 6- hydroxydopamineinduced Parkinson’s disease. Neuroscience bulletin. 2010;26(5):381-7.
19. Aziz A, Fronczek R, Maat‐Schieman M, Unmehopa U,Roelandse F, Overeem S, et al. Hypocretin and Melanin‐Concentrating Hormone in Patients with Huntington Disease. Brain pathology. 2008;18(4):474-83.
20. Fronczek R, van Geest S, Frölich M, Overeem S, Roelandse FW, Lammers GJ, et al. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiology of aging.2012;33(8):1642-50.
21. Arango MT, Kivity S, Shoenfeld Y. Is narcolepsy a classical autoimmune disease? Pharmacol Res. 2014. Epub 2014/12/03.
22. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Journal of the neurological sciences. 2006;250(1-2):120-3.
23. Takeuchi C, Yamagata K, Takemiya T. Variation in experimental autoimmune encephalomyelitis scores in a mouse model of multiple sclerosis. World J Neurol.2013;3:56-61.
24. Paxinos G, Franklin KB. The mouse brain in stereotaxic coordinates: Gulf Professional Publishing; 2004.
25. Klose J, Schmidt NO, Melms A, Dohi M, Miyazaki J-i, Bischof F, et al. Suppression of experimental autoimmune encephalomyelitis by interleukin-10 transduced neural stem/progenitor cells. Journal of neuroinflammation. 2013;10(1):117.
26. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Current opinion in neurology.2001;14(3):271-8.
27. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. Neural Cell Transplantation: Springer;2009. p. 157-73.
28. Petersén Å, Gil J, Maat-Schieman ML, Björkqvist M, Tanila H, Araújo IM, et al. Orexin loss in Huntington's disease. Human molecular genetics. 2005;14(1):39-47.
29. Drouot X, Moutereau S, Nguyen J, Lefaucheur J, Creange A, Remy P, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology.2003;61(4):540-3.
30. Constantinescu CS, Niepel G, Patterson M, Judd A, Braitch M, Fahey AJ, et al. Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. J Neurol Sci.2011;307(1-2):127-31.
31. Papuć E, Zbigniew S, Paweł G, Konrad R. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neuroscience letters. 2010;474(1):9-12.
32. Knudsen S, Jennum P, Korsholm K, Sheikh SP, Gammeltoft S, Frederiksen J. Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis. Multiple Sclerosis.2008;14(6):734-8.
33. Kato T, Kanbayashi T, Yamamoto K, Nakano T, Shimizu T, Hashimoto T, et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med. 2003;42(8):743-5. Epub 2003/08/20.
34. Oka Y, Kanbayashi T, Mezaki T, Iseki K, Matsubayashi J, Murakami G, et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis: J Neurol. 2004 Jul;251(7):885-6.
| Files | ||
| Issue | Vol 15, No 1 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| C57BL/6 mice Experimental autoimmune encephalomyelitis Multiple sclerosis Orexin 1 receptors Orexin 2 receptors Prepro-orexin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
